Cargando…

Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

PURPOSE OF REVIEW: This research paper aims to provide an overview of evidence-based sequencing of therapies in relapsed/refractory chronic lymphocytic leukemia (CLL) in the era of targeted drugs. RECENT FINDINGS: In the absence of data from randomized clinical trials comparing novel agents head-to-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Florian, Bohn, Jan-Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556156/ https://www.ncbi.nlm.nih.gov/pubmed/37682487 http://dx.doi.org/10.1007/s11912-023-01454-w

Ejemplares similares

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing
por: Gupta, Sanjeev Kumar, et al.
Publicado: (2020)

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
por: Aldapt, Mahmood B, et al.
Publicado: (2021)

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
por: Van Den Neste, Eric, et al.
Publicado: (2012)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022)

Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons
por: Rodríguez-Vicente, Ana E., et al.
Publicado: (2017)

Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing
por: Davi, Frédéric, et al.
Publicado: (2020)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
por: Shustik, C., et al.
Publicado: (2017)

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial
por: Bühler, A, et al.
Publicado: (2016)

Immunological aspects in chronic lymphocytic leukemia (CLL) development
por: García-Muñoz, Ricardo, et al.
Publicado: (2012)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
por: Sitlinger, Andrea, et al.
Publicado: (2021)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)
por: Seymour, Erlene K.
Publicado: (2019)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

Appearance and Disappearance of Chronic Myeloid Leukemia (CML) in Patient with Chronic Lymphocytic Leukemia (CLL)
por: Payandeh, Mehrdad, et al.
Publicado: (2014)

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)
por: Eichhorst, Barbara, et al.
Publicado: (2023)

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL
por: Agathangelidis, Andreas, et al.
Publicado: (2022)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Erratum to: Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations
por: Rigolin, Gian Matteo, et al.
Publicado: (2016)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups
por: Decker, Sarah, et al.
Publicado: (2019)

Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
por: Barbanti, Maria Chiara, et al.
Publicado: (2022)

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
por: Okkenhaug, Klaus, et al.
Publicado: (2015)

Optimal sequencing in the management of relapsed/refractory myeloma patients
por: Moreau, Philippe
Publicado: (2018)

Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing
por: Vollbrecht, Claudia, et al.
Publicado: (2015)

The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study
por: De Luca, Giuseppa, et al.
Publicado: (2022)

Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series
por: Flach, Johanna, et al.
Publicado: (2020)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

P625: A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
por: Byrd, John C., et al.
Publicado: (2023)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE-II CLL-FRAIL TRIAL
por: Simon, Florian, et al.
Publicado: (2023)

Next-Generation Sequencing in Acute Lymphoblastic Leukemia
por: Coccaro, Nicoletta, et al.
Publicado: (2019)

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)
por: Kater, Arnon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_92ggrabn205p1sgmivc0hditl7